Junmin Song
Clinical FellowAbout
Research
Publications
Featured Publications
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.
Park W, O'Connor CA, Chou JF, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Homsi R, Sivaprakasam K, Umeda S, Perry MA, Varghese AM, Yu KH, Balogun F, Zervoudakis A, Katz SS, Kim TH, Zhao K, Richards AL, Lecomte N, Martin Muldoon D, Karnoub E, Chatila W, Yang J, El-Dika I, Rao D, Joshi S, Foote MB, Sugarman R, Harding JJ, Epstein AS, Kelsen D, Chalassani S, Keane F, Schoenfeld JD, Singhal A, Diguglielmo E, Bandlamudi C, Song J, Ozkan HS, Hong J, Zhang H, Cardenas AI, Lao M, Melchor J, Shah R, Kang W, Mazzoni F, Soares K, Donoghue MT, Santos E, Rolston V, Reyngold M, Wei AC, Tipping M, Basturk O, Berger M, Kihn Do R, Schattner M, Jarnagin WR, Riaz N, Balachandran V, Pe'er D, Capanu M, Iacobuzio-Donahue C, O'Reilly EM. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Nat Med 2026, 32: 1783-1793. PMID: 41882405, DOI: 10.1038/s41591-026-04299-5.Peer-Reviewed Original ResearchThoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches
Song J, Gersten A, Herzberg B, Halmos B. Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches. The Oncologist 2025, 30: oyaf121. PMID: 40421964, PMCID: PMC12107547, DOI: 10.1093/oncolo/oyaf121.Peer-Reviewed Original ResearchConceptsSMARCA4-UTThoracic SMARCA4-deficient undifferentiated tumorSMARCA4-deficient undifferentiated tumorAggressive clinical behaviorTargeted clinical trialsThoracic tumorsUndifferentiated tumorsHistological presentationClinical behaviorPoor prognosisDifferential diagnosisImmunohistochemical evaluationEffective therapyDiagnostic pathwayClinical trialsDisease entityMolecular basisMolecular evaluationTumorThoracicDiagnosisTreatment implicationsDiagnostic complexPrognosisTherapyTreatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC.
Lee M, Song J, Miao E, Alicea DS, Zhang C, Xue X, Tuckman S, Yang J, D'Aiello A, Gucalp R, Stiles B, Ohri N, Halmos B, Cheng H. Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC. NPJ Precis Oncol 2026, 10 PMID: 41593317, DOI: 10.1038/s41698-025-01259-z.Peer-Reviewed Original ResearchTeclistamab versus B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis
Song J, Chiang C, Esagian S, Kim G, Chi K, Chang Y, Parker T, Mehta A. Teclistamab versus B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis. Haematologica 2025, 110: 2498-2502. PMID: 40207713, PMCID: PMC12485301, DOI: 10.3324/haematol.2024.287215.Peer-Reviewed Original ResearchGlucagon-like Peptide‐1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors
Chiang C, Song J, Chi K, Chang Y, Xanthavanij N, Chang Y, Hsia Y, Chiang C, Ghamari A, Reynolds K, Lin S, Xu X, Neilan T. Glucagon-like Peptide‐1 Agonists Reduce Cardiovascular Events in Cancer Patients on Immune Checkpoint Inhibitors. European Journal Of Cancer 2024, 216: 115170. PMID: 39709670, DOI: 10.1016/j.ejca.2024.115170.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1 agonistsImmune checkpoint inhibitorsImmune-related adverse eventsSerious adverse eventsAdverse eventsAll-Cause MortalityCardiovascular eventsCheckpoint inhibitorsEfficacy outcomesCoronary revascularizationHeart failureOccurrence of immune-related adverse eventsCancer patientsLower risk of MACEMedian 12-month follow-upLow riskMyocardial infarctionComposite of myocardial infarctionRisk of adverse eventsRisk of MACEType 2 diabetes mellitusReduce cardiovascular eventsIndividual components of MACEComponents of MACEPeptide-1 agonistsGLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance
Chi K, Song J, Desphande S, Lee P, Soni A, Gonzales-Uribe A, Lessa Y, Morgan A, Chang Y, Lin Y, Akman Z, Nouri A, Rossi R, Babapour G, Varrias D, Parker T, Baldassarre L, Jha A, Muchtar E, Hull S, Kwan J, Nanna M. GLP-1 RA Use and Major Adverse Cardiovascular Events in Patients With Monoclonal Gammopathy of Undetermined Significance. JAMA Network Open 2025, 8: e2517541. PMID: 40587132, PMCID: PMC12210086, DOI: 10.1001/jamanetworkopen.2025.17541.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-1GLP-1 RAsNew-onset HFAcute kidney injuryEnd-stage kidney diseaseScore matching analysisPrimary preventionMonoclonal gammopathyTransient ischemic attackCohort studyDecompensated HFMGUS diagnosisRA usersKidney injuryHeart failureRA useKidney diseaseIschemic attackEffects of GLP-1 RAsMajor adverse cardiovascular eventsProspective randomized trialsSecondary end pointsRisk of cardiovascular diseaseRetrospective cohort studyAdverse cardiovascular eventsGlucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation
Chiang C, Song J, Chang Y, Osataphan S, Lee Y, Chang K, Chi K, Chiang C, Dua A, Lake L, Lauw M, Bauer K, Kazi D, Patell R. Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation. Blood Advances 2025, 9: 2410-2418. PMID: 39908569, PMCID: PMC12142527, DOI: 10.1182/bloodadvances.2025015871.Peer-Reviewed Original ResearchConceptsDipeptidyl peptidase-4 inhibitorsGlucagon-like peptide 1 receptor agonistsPeptide 1 receptor agonistsRisk of venous thromboembolismGLP1-RA useTarget trial emulationGLP1-RAVenous thromboembolismPopulation-based databaseLow risk of venous thromboembolismLow riskMonths of follow-upIncidence of venous thromboembolismTrial emulationType 2 diabetes mellitusPeptidase-4 inhibitorsDeep vein thrombosisElectronic health recordsDatabase of electronic health recordsType 2 diabetesPulmonary embolismVein thrombosisPreclinical studiesHealth recordsFollow-upUpdate 2025: Management of Non‑Small-Cell Lung Cancer.
Jeon H, Wang S, Song J, Gill H, Cheng H. Update 2025: Management of Non‑Small-Cell Lung Cancer. Lung 2025, 203: 53. PMID: 40133478, DOI: 10.1007/s00408-025-00801-x.Peer-Reviewed Original Research
2026
Sequencing strategy of immunotherapy with chemoradiotherapy in stage III non–small cell lung cancer: A pooled analysis of prospective trials.
Li Y, Song J, Song X, Zhang X, Stefani H, Ezhilarasu P, Li F, Ohri N, Cheng H. Sequencing strategy of immunotherapy with chemoradiotherapy in stage III non–small cell lung cancer: A pooled analysis of prospective trials. Journal Of Clinical Oncology 2026, 44: e20041-e20041. DOI: 10.1200/jco.2026.44.16_suppl.e20041.Peer-Reviewed Original ResearchGLP-1 Receptor Agonist Use and Survival Among Patients With Type 2 Diabetes and Brain Metastases
Chi K, Chang Y, Song J, Chen C, Perng P, Lin H. GLP-1 Receptor Agonist Use and Survival Among Patients With Type 2 Diabetes and Brain Metastases. JAMA Network Open 2026, 9: e261311. PMID: 41811319, PMCID: PMC12980253, DOI: 10.1001/jamanetworkopen.2026.1311.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Get In Touch
Contacts
Email